CytoDyn (OTCQB: CYDY), a biotechnology company developing a
novel humanized CCR5 monoclonal antibody for multiple therapeutic indications,
this morning announced that company management is set to present at two
upcoming conferences. First, the company will give a presentation at the Fourth
Annual Robins Equity Research Roundup in Portland, Oregon on Tuesday, September
25, 2018 at 10:00 a.m. Pacific time. Next, CytoDyn will present at The MicroCap
Conference at the Essex House in New York City on Monday, October 1, at 9:00
a.m. ET. A live webcast and replay of the company’s presentation at The
MicroCap Conference will be accessible on the company’s website.
To view the full press release, visit http://ibn.fm/ZxHk8
About CytoDyn
CytoDyn is a biotechnology company focused on the clinical
development and potential commercialization of humanized monoclonal antibodies
for the treatment and prevention of HIV infection. The Company has one of the
leading monoclonal antibodies under development for HIV infection, PRO 140,
which has completed Phase 2 clinical trials with demonstrated antiviral
activity in humans and is currently in Phase 3 development. PRO 140 blocks the
HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial
results thus far indicate that PRO 140 does not negatively affect the normal
immune functions that are mediated by CCR5. Results from seven Phase 1 and
Phase 2 human clinical trials have shown that PRO 140 can significantly reduce
viral burden in people infected with HIV. A recent Phase 2b clinical trial
demonstrated that PRO 140 can prevent viral escape in patients during several
months of interruption from conventional drug therapy. CytoDyn intends to
continue to develop PRO 140 as a therapeutic anti-viral agent in persons
infected with HIV and to pursue non-HIV, inflammatory indications where CCR5
and its ligand CCL5 may be involved. For more information, visit the company’s
website at www.CytoDyn.com
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and more,
these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
QualityStocks has received compensation from CytoDyn Inc.
for providing certain investor relations, marketing and social media services,
including the preparation of this report, and expects to receive additional
compensation for such services in the future. This compensation includes a
monthly program fee.
No comments:
Post a Comment